Prazer Therapeutics is a pioneering biotechnology company focused on the development of innovative therapies targeting previously untreatable diseases. Utilizing its proprietary SPiDEM™ (Selective Protein Degradation Enabling Moiety) platform, PRazer aims to overcome the limitations of first-generation targeted protein degradation (TPD) modalities, such as PROTACs and molecular glue degraders (MGDs). SPiDEM™ merges the best features of these approaches, offering broader therapeutic applications, including the degradation of membrane and aggregated proteins via both proteasome and lysosome pathways. Founded in 2019, Prazer is headquartered in Seoul, Korea, and is at the forefront of next-generation TPD technology. With key partnerships, including collaborations with leading pharmaceutical companies like Yuhan Corporation and Daewon Pharmaceutical. Prazer is committed to expanding its therapeutic pipeline, targeting diseases such as cancer, Alzheimer’s, and Parkinson’s.